Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Research » Research Programs
  • Research Programs
    • Taclantis® (PICS)
    • SCO - 088
    • SCD - 044
    • SCC - 138
    • SCO - 120

SCC - 138

More than 10 million people worldwide are suffering from Parkinson’s disease1. The available therapies are largely symptomatic and there are no truly disease modifying treatment options available as yet that can protect the loss of dopamine producing neurons.

SCC - 138, is a potent, orally active, and exhibits superior safety / tolerability profile. In MPTP mouse model SCC - 138 protects the loss of the dopamine-producing neurons.

SUN–K0706_pd

SPARC has completed two Phase 1 studies with no observed significant adverse events in both studies. The preliminary pharmacokinetic data indicate the presence of drug in the CSF, suggesting that the drug is able to get to its site of intended action.

We have initiated a Phase 2 Study (PROSEEK) to evaluate the efficacy, safety and tolerability of SCC-138 in subjects with early Parkinson's Disease (PD) who are not receiving dopaminergic therapy.

For more details on the PROSEEK study visit: www.proseekstudy.com

1. Parkinson’s Disease Foundation - http://www.pdf.org/parkinson_statistics

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits